SHORELINE BIOSCIENCES APPOINTS KIMBERLY MANHARD TO BOARD OF DIRECTORS

San Diego, Calif., May 19, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of  Kimberly Manhard as a member of the Board of Directors. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations, and has been instrumental in the development and approval of eight drugs across multiple therapeutic categories. 

 

“We are very pleased to have such an accomplished drug developer and regulatory expert like Kimberly join our board as we continue to grow Shoreline,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Chairman and CEO.  “Kimberly has a diversified background both as an industry executive, and board member who is responsible for delivering eight important commercial drugs to patients.  We are thrilled to welcome Kimberly to our board and look forward to gaining valuable insights as we advance our cell therapy programs toward the clinic and beyond.”

 

“Shoreline has great potential to improve the development of safe, effective and affordable allogeneic cell therapies and carve out a leading position in the dynamic field of immunotherapy,” commented Ms. Manhard. “I am pleased to join such an experienced board and look forward to leveraging my experience to guide Shoreline in the successful development of iPSC-derived allogeneic cell immunotherapies.”

 

Ms. Manhard currently serves as Executive Vice President, Drug Development and director of Heron Therapeutics, where she has played a key role in the development and regulatory approvals of oncology care products Sustol® and Cinvanti® and Zynrelef™ for postoperative pain.  Prior to joining Heron, Ms. Manhard served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc. (acquired by AstraZeneca), where she was was key to the development and regulatory approval of Zurampic® (lesinurad). Prior to joining Ardea, she was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept® (nelfinavir).  Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol® (paclitaxel) and infectious disease compounds, including Videx® (didanosine) and Zerit® (stavudine). She began her career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.).  Ms. Manhard also currently serves as a member of the board of directors of InhibRx, Inc. and Shoreline Biosciences and is a member of the board of trustees for the Fleet Science Center.  She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.

For more information, please engage with us on LinkedIn.

Shoreline Biosciences Investor and Media
Contact:
Amy Conrad Juniper
Pointamy@juniper-point.com
858-366-3243

 

Shoreline Biosciences Appoints Vanessa L. Jacoby as Chief Financial Officer

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of Vanessa L. Jacoby as Chief Financial Officer.Ms. Jacoby brings more than twenty years of experience as a financial leader to Shoreline, with a strong background in company building and financial strategy.

“I am pleased to welcome Vanessa to Shoreline as our Chief Financial Officer,”said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder and Executive Chairman. “Vanessa’s recent IPO and public markets experience,coupled with a proven track record in building and financing companies through critical phases of growth,will be invaluable to our team as we grow into a domain-dominant cell therapy player.”“I am thrilled to be joining Shoreline at this exciting stage of its development. Shoreline’s vision of developing allogeneic cell therapies has the potential to change the lives of critically ill patients and is a unique and compelling opportunity,” said Ms. Jacoby. “I look forward to utilizing my experience to fulfill Shoreline’s strategic and financial objectives to become a leading cell therapy company.”

Ms. Jacoby has extensive experience in the biotechnology and life science sectors, having served as a senior financial executive of several private and public companies. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc., where she led all corporate finance and planning activities and played a key role in the company’s $300M Initial Public Offering in June 2020and $100M Series C in October 2019. Prior to Avidity, Ms. Jacoby was Vice President, Finance at Pharm Akea, which was acquired by Galecto in 2019. Prior to that,she served as a Director of Accounting and Controller at BCI, Inc. and held senior financial roles at Artes Medical and Verenium.Before joining industry, Ms. Jacoby was an auditor for Ernst & Young and she is a certified public accountant with the State of California (inactive). Ms Jacoby received her M.B.A. from National University and B.S. degree in Business Administration from Fundação Armando Alvares Penteado, Sao Paulo, Brazil.

For more information, please engage with us on LinkedIn.

Shoreline Biosciences Investor and Media
Contact:
Amy Conrad Juniper
Pointamy@juniper-point.com
858-366-3243